Technical Analysis for MRSN - Mersana Therapeutics, Inc.

Grade Last Price % Change Price Change
F 18.28 1.05% 0.19
MRSN closed down 1.26 percent on Thursday, March 4, 2021, on 82 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical MRSN trend table...

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 1.05%
Wide Bands Range Expansion 1.05%
Down 3 Days in a Row Weakness 1.05%
Oversold Stochastic Weakness 1.05%
Wide Bands Range Expansion -0.22%
180 Bearish Setup Bearish Swing Setup -4.84%
Multiple of Ten Bearish Other -4.84%
Wide Bands Range Expansion -4.84%
Oversold Stochastic Weakness -4.84%
Slingshot Bearish Bearish Swing Setup -7.58%
Older End-of-Day Signals for MRSN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 3 hours ago
Down 3% about 4 hours ago
Fell Below Previous Day's Low about 5 hours ago
Down 2 % about 5 hours ago
Down 1% about 5 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Mersana Therapeutics, Inc. Description

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Development Immunology Cancers Monoclonal Antibodies Chemotherapy Antibody Drug Conjugates Linker Synaffix

Is MRSN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 29.09
52 Week Low 4.12
Average Volume 1,172,944
200-Day Moving Average 20.73
50-Day Moving Average 21.43
20-Day Moving Average 20.81
10-Day Moving Average 19.02
Average True Range 1.32
ADX 20.72
+DI 16.36
-DI 30.79
Chandelier Exit (Long, 3 ATRs ) 20.43
Chandelier Exit (Short, 3 ATRs ) 21.34
Upper Bollinger Band 24.81
Lower Bollinger Band 16.80
Percent B (%b) 0.16
BandWidth 38.47
MACD Line -0.85
MACD Signal Line -0.60
MACD Histogram -0.2483
Fundamentals Value
Market Cap 1.24 Billion
Num Shares 68.5 Million
EPS -1.12
Price-to-Earnings (P/E) Ratio -16.21
Price-to-Sales 1506.75
Price-to-Book 6.22
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.03
Resistance 3 (R3) 20.09 19.50 19.70
Resistance 2 (R2) 19.50 19.01 19.47 19.59
Resistance 1 (R1) 18.80 18.71 18.51 18.74 19.49
Pivot Point 18.21 18.21 18.07 18.18 18.21
Support 1 (S1) 17.51 17.72 17.22 17.45 16.69
Support 2 (S2) 16.92 17.42 16.89 16.59
Support 3 (S3) 16.22 16.92 16.48
Support 4 (S4) 16.16